BioVaxys Technology Corp., announced that a poster highlighting its preclinical data on BVX-0320, the Company’s SARS-CoV-2 vaccine candidate based on its haptenized viral protein technology, will be presented at a joint Virtual Congress of the International Society for Influenza and other Respiratory Virus Diseases and the World Health Organization, which is being held October 19-21, 2021.
October 8, 2021
· 5 min read